Portland, Oregon 97239


The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

Study summary:

Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as PD progresses. Attention deficits in PD patients with dementia strongly predict the impairment of their daily living activities. Previous studies have shown that atomoxetine improves PD executive dysfunction and rivastigmine improves attention deficits in PD patients with dementia without worsening the motor symptoms. The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention and quality of life in PD patients without disabling cognitive impairment.


Inclusion Criteria: - Clinical diagnosis of Parkinson's disease - Respond to levodopa therapy Exclusion Criteria: - Dementia - Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD - Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization - Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders); - Currently using any of the study drugs; - Colorblindness



Primary Contact:

Principal Investigator
Jau-Shin Lou, MD, PhD
Oregon Health and Science University

Diana Dimitrova, PhD
Phone: 503-494-7269
Email: dimitrov@ohsu.edu

Backup Contact:


Location Contact:

Portland, Oregon 97239
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.